Related Experiment Videos
High-dose chemotherapy for breast cancer
1Western General Hospital, University of Edinburgh, U.K.
European Journal of Cancer (Oxford, England : 1990)
|February 1, 1996
Summary
Dose-intensive chemotherapy shows promise, with peripheral blood progenitor cells (PBPC) replacing autologous bone marrow transplantation (ABMT). Rigorous trials are essential to evaluate risks and benefits of these advanced cancer treatments.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- Conventional chemotherapy analysis fuels interest in dose-intensive approaches.
- Combination alkylating agents are favored for maximizing anti-cancer effects and stem cell rescue.
- Peripheral blood progenitor cells (PBPC) are now standard over autologous bone marrow transplantation (ABMT).
Purpose of the Study:
- To evaluate the evolving landscape of dose-intensive chemotherapy and stem cell rescue techniques.
- To highlight the need for rigorous controlled trials in high-dose cancer therapy.
- To address patient selection and tumor contamination concerns in metastatic disease.
Main Methods:
- Review of laboratory studies and retrospective analyses of chemotherapy regimens.
- Comparison of PBPC versus ABMT for stem cell rescue.
- Ongoing examination of tumor contamination in blood and bone marrow harvests.
Main Results:
- PBPC offers faster engraftment and potentially reduced acute complications compared to ABMT.
- The long-term risks of late engraftment with PBPC require further study.
- Interest is growing in sequential myeloablative treatments supported by early-collected stem cells.
Conclusions:
- While promising, the full impact of PBPC and dose-intensive regimens remains to be seen.
- Patient selection in metastatic disease requires greater attention.
- The high costs of high-dose therapy necessitate controlled trials to avoid unproven practices.